Back to Search
Start Over
Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review.
- Source :
-
The American journal of gastroenterology [Am J Gastroenterol] 2021 Jun 01; Vol. 116 (6), pp. 1156-1181. - Publication Year :
- 2021
-
Abstract
- Introduction: Constipation is commonly treated with over-the-counter (OTC) products whose efficacy and safety remain unclear. We performed a systematic review of OTC therapies for chronic constipation and provide evidence-based recommendations.<br />Methods: We searched PubMed and Embase for randomized controlled trials of ≥4-week duration that evaluated OTC preparations between 2004 and 2020. Studies were scored using the US Preventive Services Task Force criteria (0-5 scale) including randomization, blinding, and withdrawals. The strengths of evidence were adjudicated within each therapeutic category, and recommendations were graded (A, B, C, D, and I) based on the level of evidence (level I, good; II, fair; or III, poor).<br />Results: Of 1,297 studies identified, 41 met the inclusion criteria. There was good evidence (grade A recommendation) for the use of the osmotic laxative polyethylene glycol (PEG) and the stimulant senna; moderate evidence (grade B) for psyllium, SupraFiber, magnesium salts, stimulants (bisacodyl and sodium picosulfate), fruit-based laxatives (kiwi, mango, prunes, and ficus), and yogurt with galacto-oligosaccharide/prunes/linseed oil; and insufficient evidence (grade I) for polydextrose, inulin, and fructo-oligosaccharide. Diarrhea, nausea, bloating, and abdominal pain were common adverse events, but no serious adverse events were reported.<br />Discussion: The spectrum of OTC products has increased and quality of evidence has improved, but methodological issues including variability in study design, primary outcome measures, trial duration, and small sample sizes remain. We found good evidence to recommend polyethylene glycol or senna as first-line laxatives and moderate evidence supporting fiber supplements, fruits, stimulant laxatives, and magnesium-based products. For others, further validation with more rigorously designed studies is warranted.<br /> (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
- Subjects :
- Bisacodyl
Cathartics therapeutic use
Chronic Disease
Citrates
Fruit
Glucans
Humans
Inulin
Laxatives therapeutic use
Magnesium
Oligosaccharides
Organometallic Compounds
Picolines
Polyethylene Glycols
Psyllium
Senna Extract
Yogurt
Constipation drug therapy
Defecation drug effects
Gastrointestinal Agents therapeutic use
Nonprescription Drugs therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1572-0241
- Volume :
- 116
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- The American journal of gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- 33767108
- Full Text :
- https://doi.org/10.14309/ajg.0000000000001222